Antifibrillizing agents catalyze the formation of unstable intermediate aggregates of beta-amyloid

Biotechnology Progress

Volumn 26, Issue 4, 2010, Pages 1172-1179

  Wang, Min S ^a,b   Boddapati, Shanta ^a   Sierks, Michael R ^a  

^a Arizona State University   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Aggregation; Alzheimer's disease; Beta amyloid; Fibrils; Oligomers

Indexed keywords

AGGREGATE SPECIES; AGGREGATION; AGGREGATION KINETICS; AGGREGATION MECHANISM; AGGREGATION STRATEGY; ALZHEIMER'S DISEASE; BETA-AMYLOID; EXTRACELLULAR; FIBRIL FORMATION; FIBRILLAR AGGREGATES; FIBRILS; HUMAN NEUROBLASTOMA; NUCLEATION MECHANISM; THERAPEUTIC AGENTS;

AGGREGATES; DISEASES; GLYCOPROTEINS; OLIGOMERS; SUGAR (SUCROSE);

TOXICITY;

AMYLOID; AMYLOID BETA PROTEIN; MANNOSE; RAFFINOSE; SUCROSE;

ARTICLE; ATOMIC FORCE MICROSCOPY; DRUG EFFECT; HUMAN; KINETICS; METABOLISM; TEMPERATURE; TUMOR CELL LINE;

AMYLOID; AMYLOID BETA-PEPTIDES; CELL LINE, TUMOR; HUMANS; KINETICS; MANNOSE; MICROSCOPY, ATOMIC FORCE; RAFFINOSE; SUCROSE; TEMPERATURE;

EID: 77956976942     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.396     Document Type: Article

References (36)

1. Koo EH, Lansbury PT, Kelly JW. Amyloid diseases: abnormal protein aggregation in neurodegeneration. Proc Natl Acad Sci USA. 1999;96:9989-9990.
2. Ceru S, Zerovnik E. Similar toxicity of the oligomeric molten globule state and the prefibrillar oligomers. FEBS Lett. 2008; 582:203-209.
3. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 1999;38: 8972-8980.
4. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, Glabe CG. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486-489.
5. Baglioni S, Casamenti F, Bucciantini M, Luheshi LM, Taddei N, Chiti F, Dobson CM, Stefani M. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J Neurosci. 2006;26:8160-8167.
6. Harper JD, Wong SS, Lieber CM, Lansbury PT. Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease. Biochemistry. 1999;38:8972-8980.
7. Kayed R, Bernhagen J, Greenfield N, Sweimeh K, Brunner H, Voelter W, Kapurniotu A. Conformational transitions of islet amyloid polypeptide (IAPP) in amyloid formation in vitro. J Mol Biol. 1999;287:781-796.
8. Lomakin A, Chung DS, Benedek GB, Kirschner DA, Teplow DB. On the nucleation and growth of amyloid beta-protein fibrils: detection of nuclei and quantitation of rate constants. Proc Natl Acad Sci USA. 1996;93:1125-1129.
9. Harper JD, Lansbury PT. Models of amyloid seeding in Alzheimier's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Ann Rev Biochem. 1997;66:385-407.
10. Harper JD, Lieber CM, Lansbury PT Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol. 1997;4:951-959.
11. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ, Teplow DB. Amyloid beta-protein fibrillogenesis-structure and biological activity of protofibrillar intermediates. J Biol Chem. 1999;274: 25945-25952.
12. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Bio Chem. 2007;282:10311-10324.
13. Uversky VN, Cooper EM, Bower KS, Li J, Fink AL. Accelerated alpha-synuclein fibrillation in crowded milieu. FEBS Lett. 2002;515:99-103.
14. Fung J, Darabie AA, McLaurin J. Contribution of simple saccharides to the stabilization of amyloid structure. Biochem Biophys Res Commun. 2005;328:1067-1072.
15. Hatters DM, Minton AP, Howlett GJ. Macromolecular crowding accelerates amyloid formation by human apolipoprotein C-II. J Biol Chem. 2002;277:7824-7830.
16. Minton AP. The influence of macromolecular crowding and macromolecular confinement on biochemical reactions in physiological media. J Biol Chem. 2001;276:10577-10580.
17. Munishkina LA, Cooper EM, Uversky VN, Fink AL. The effect of macromolecular crowding on protein aggregation and amyloid fibril formation. J Mol Recogn. 2004;17:456-464.
18. Shtilerman MD, Ding TT, Lansbury PT. Molecular crowding accelerates fibrillization of alpha-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry. 2002;41:3855-3860.
19. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Neuropharmacology. 2005; 49:1088-1099.
20. Ono K, Naiki H, Yamada M. The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fA beta), as well as destabilize preformed fA beta. Curr Pharm Des. 2006;12:4357-4375.
21. Porat Y, Abramowitz A, Gazit E. Inhibition of amyloid fibril formation by polyphenols: structural similarity and aromatic interactions as a common inhibition mechanism. Chem Biol Drug Des. 2006;67:27-37.
22. Zameer A, Kasturirangan S, Emadi S, Nimmagadda SV, Sierks MR. Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells. J Mol Biol. 2008;384:917-928.
23. LeVine H. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 1999;309:274-284.
24. Zameer A, Schulz P, Wang MS, Sierks MR. Single chain Fv antibodies against the 25-35 A beta fragment inhibit aggregation and toxicity of A beta 42. Biochemistry. 2006;45:11532-11539.
25. Decker T, Lohmannmatthes ML. A quick and simple method for the quantitation of lactate-dehydrogenase release in measurements of cellular cyto-toxicity and tumor necrosis factor (Tnf) activity. J Immunol Methods. 1988;115:61-69.
26. Ahmed SA, Gogal RM, Walsh JE. A new rapid and simple nonradioactive assay to monitor and determine the proliferation of lymphocytes-an alternative to [H-3] thymidine incorporation assay. J Immunol Methods. 1994;170:211-224.
27. Shahan TA, Siegel PD, Sorenson WG, Kuschner WG, Lewis DM. A sensitive new bioassay for tumor-necrosis-factor. J Immunol Methods. 1994;175:181-187.
28. Kusumoto Y, Lomakin A, Teplow DB, Benedek GB. Temperature dependence of amyloid beta-protein fibrillization. Proc Natl Acad Sci USA. 1998;95:12277-12282.
29. Sabate R, Gallardo M, Estelrich J. Temperature dependence of the nucleation constant rate in beta amyloid fibrillogenesis. Int J Biol Macromol. 2005;35:9-13.
30. Sabate R, Gallardo M, Estelrich J. An autocatalytic reaction, as a model for the kinetics of the aggregation of beta-amyloid. Biopolymers. 2003;71:190-195.
31. Cohen T, Frydman-Marom A, Rechter M, Gazit E. Inhibition of amyloid fibril formation and cytotoxicity by hydroxyindole derivatives. Biochemistry. 2006;45:4727-4735.
32. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR. Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis. 2005;20:74-81.
33. Miura Y, Yasuda K, Yamamoto K, Koike M, Nishida Y, Kobayashi K. Inhibition of alzheimer amyloid aggregation with sulfated glycopolymers. Biomacromolecules. 2007;8:2129-2134.
34. Miura Y, You C, Ohnishi R. Inhibition of Alzheimer amyloid beta aggregation by polyvalent trehalose. Sci Technol Adv Mater. 2008;9:024407.
35. Yang DS, Yip CM, Huang THJ, Chakrabartty A, Fraser PE. Manipulating the amyloid-beta aggregation pathway with chemical chaperones. J Biol Chem. 1999;274:32970-32974.
36. Takahashi Y, Ueno A, Mihara H. Design of a peptide undergoing alpha-beta structural transition and amyloid fibrillogenesis by the introduction of a hydrophobic defect. Chem Eur J. 1998;4:2475-2484.